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Abstract
Background: A growing body of research suggests that regular consumption of dairy foods may counteract
obesity and other components of the metabolic syndrome. However, human intervention trials are lacking. We
aimed to determine the cardiometabolic health effects of increasing the consumption of reduced fat dairy foods in
adults with habitually low dairy intakes in the absence of energy restriction.
Methods: An intervention trial was undertaken in 61 overweight or obese adults who were randomly assigned to
a high dairy diet (HD, 4 serves of reduced fat dairy/day) or a low dairy control diet (LD, ≤1 serve/day) for 6 months
then crossed over to the alternate diet for a further 6 months. A range of anthropometric and cardiometabolic
parameters including body composition, metabolic rate, blood lipids, blood pressure and arterial compliance were
assessed at the end of each diet phase.
Results: Total energy intake was 1120 kJ/day higher during the HD phase, resulting in slight weight gain during
this period. However, there were no significant differences between HD and LD in absolute measures of waist
circumference, body weight, fat mass or any other cardiometabolic parameter.
Conclusion: Recommended intakes of reduced fat dairy products may be incorporated into the diet of overweight
adults without adversely affecting markers of cardiometabolic health.
Trial Registration: The trial was registered with the Australia and New Zealand Clinical Trials Registry
(ACTRN12608000538347) on 24th October, 2008.
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Background
Obesity has become a worldwide health epidemic [1].
With obesity related health costs exceeding billions of
dollars in both Australia [2] and the United States [3],
easily implemented interventions to slow or prevent
obesity via weight loss has become a health priority.
Dairy products provide over half of the dietary intake
of calcium in most parts of the Western world [4]. In
addition to calcium, dairy is an important dietary source
of protein, vitamin D, potassium, phosphorus and mag-
nesium. Clinical trials show that increasing dietary cal-
cium and dairy intake can enhance weight and fat loss
and preserve lean muscle mass during energy restriction,
with dairy products exerting greater effects on attenuat-
ing adiposity than calcium supplementation alone [5-7].
However, other studies have failed to find any effect of a
high intake of dairy food on body weight in an energy-
restricted diet [8-10]. Without energy restriction, there
is little evidence for the role of high-dairy or high-cal-
cium diets in weight or fat loss. As summarised in a
thorough review by Lanou and Barnard [11], of 10 ran-
domised controlled trials examining the effects of dairy
products on body weight in adults, eight studies found
no effect [12-19], and the remaining two found increases
in body weight with increased dairy intake [20,21]. Only
one study has reported reductions in total body fat in
response to a high dairy diet, without energy restriction
and in the absence of weight loss [19]. These discrepan-
cies may be due to a number of factors including
aspects of study design, such as treatment length, sam-
ple size, body weight at baseline, quantity of dairy added
to the diet, as well as habitual dairy or calcium intake
prior to intervention or energy restriction. Clearly, the
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evidence to support a beneficial effect of a high intake
of dairy food on body weight or composition.
Dairy products may have potentially advantageous
effects on other metabolic risk factors via beneficial
effects on blood pressure [22-24], type 2 diabetes [25,26]
and the metabolic syndrome [22,27-31], all of which are
cardiovascular disease (CVD) risk factors. However
much of what is currently known about dairy intake and
cardiometabolic health comes from cross-sectional or
longitudinal studies which lack the ability to show caus-
ality. The limitations within this literature to date, sum-
marised in a recent systematic review [32], do not allow
conclusions to be drawn about the specific type and
amount of dairy associated with any benefit.
Evidence from high-quality randomised controlled
trials is needed to ascertain the effects of long-term con-
sumption of reduced fat dairy food on body weight and
composition, in addition to other cardiometabolic mea-
sures. The aim of this study is to monitor the effects of
reduced fat dairy products on the primary outcome
measure, waist circumference, in addition to other mar-
kers of cardiometabolic disease, in an at-risk population.
Waist circumference was chosen as the primary out-
come measure as it is a simple, reproducible measure of
adiposity that people can easily understand. It is
hypothesised that a high intake of reduced fat dairy food
will have a beneficial effect on waist circumference and
other markers of cardiometabolic health.
Methods
Participants
Participants were recruited via multiple strategies,
including advertisements seeking people to participate
in a trial examining the health benefits of dairy, placed
in a local newspaper, on notice-boards around the uni-
versity and in several public places (local hospital,
libraries and shopping centres). During the recruitment
period, a short interview segment on a current affairs
program was shown on local television promoting the
study and discussing the possible health benefits of
dairy. Interested potential volunteers were invited to an
information session and pre-study screening in which
some simple health measures were taken (height, weight,
blood pressure) and health and dietary questionnaires
were completed to determine eligibility for inclusion in
the study.
Participants were overweight or obese men and
women (BMI ≥ 25 kg/m
2), aged 18 to 75 years, who had
a self-reported habitually low intake of dairy (< 2 serves/
day). Low dairy consumers were selected in order to be
representative of the Australian population in terms of
dairy consumption, with the most recent national nutri-
tional survey indicating that the average Australian adult
consumes between 1 to 1.5 serves of dairy/day [33],
where one serve equates to 250 mL of milk, 40 g of
cheese or 200 g of yoghurt [34]. Similarly, overweight
people were chosen as they represent the majority of
the population. Recent estimates indicate that 60% of
Australian adults are overweight or obese [35], and
these individuals have a greater likelihood of having
other components of metabolic syndrome.
An upper weight limit was set at 135 kg, as this is the
maximum capacity of the dual energy X-ray absorptio-
metry (DEXA) used to assess body composition. Other
exclusion criteria included being a current smoker, diag-
nosed with diabetes, CVD, liver disease, renal disease or
stage 2 hypertension (> 160/100 mm Hg), pregnancy or
the possibility of pregnancy within 12 months. Con-
sumption of more than 1 g of fish oil/day, regular use of
appetite suppressants, weight loss medications, or any
other medication that may have influenced the study
outcomes prevented inclusion. Participants were
excluded if they had a known allergy or intolerance to
dairy or lactose, or were considered unlikely to comply
with the study protocol.
Ethical approval for the study was obtained from the
University of South Australia Human Research Ethics
Committee and all participants provided written
informed consent prior to participating. Participants
were offered AUD$200 upon completion of the study to
compensate them for travel expenses incurred as a
result of participation in the study.
Study design and procedure
The 12-month dietary intervention trial was conducted at
the Nutritional Physiology Research Centre, Adelaide,
South Australia. Participants were randomised, with stra-
tification by age and gender, to a high dairy diet (HD; 4
serves of reduced fat dairy/day) or a low dairy control
diet (LD; 1 serve of reduced fat dairy/day) for 6 months,
after which they crossed over to the alternate diet for a
further 6 months. Participants were instructed to con-
tinue with their normal physical activity for the duration
of the study. A crossover design was implemented to
enable comparison of each condition within the same
individual and ensure individual differences are controlled
for, thereby reducing the sample size required to find a
significant effect due to increased statistical power [36].
This design was also adopted to minimise attrition and
maximise participant interest and compliance by enabling
each participant to experience both diet conditions and
receive complimentary dairy food. Based on waist circum-
ference, the primary outcome measure, a total sample of
34 was estimated to give 80% power to detect an effect
size of 0.5 (predicted change/SD of change) at an alpha
of 0.05 [37]. This represents a detectable change in waist
circumference of 1.8 cm.
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During this study arm, participants were required to
consume 4 serves of reduced fat dairy/d for 6 months.
Fifty-six serves of dairy were given to each participant
on a fortnightly basis. Verbal and written information
was given to all participants specifying serving sizes for
different dairy foods. The reduced fat products provided
were milk, flavoured milk, natural and flavoured yogurt,
and vanilla custard. One serve of dairy equated to 250
mL (1 cup) of milk, 175-200 g (1 small tub) of yogurt,
and 190 g (¾ cup) of custard. Each serve provided
approximately 500 kJ, 2 g of fat (1.2 g saturated fat), 9 g
of protein, 19 g of carbohydrate (18 g sugars). A selec-
tion of these foods was provided based on personal pre-
ference. All participants were instructed to incorporate
the dairy into their diet by substituting other foods for
dairy in an effort to avoid increasing their overall energy
intake.
Participants were permitted to consume a small
amount of dairy foods other than those provided for the
study, but were asked to limit this to reduced fat vari-
eties and to consume no more than an additional 7
serves/wk. Standard serving sizes for additional dairy
were 40 g (2 slices) of cheese, 100 g of cottage cheese,
30 g (1 tablespoon) of ricotta, cream cheese or cream,
90 g (2 scoops) of ice-cream, and 11 g (1 teaspoon) of
butter or margarine. These are standard serving sizes as
defined by the Australian Dietary Guidelines [34]. Com-
pliance with the HD diet was measured through the
completion of weekly dairy logs, in which participants
recorded all dairy consumed (type and quantity), includ-
ing dairy foods consumed in addition to those provided
for the study. The quantity of dairy provided was
reduced for participants who regularly consumed their
own preferred dairy products to ensure total intake did
not exceed 28 serves/week. Participants were weighed
fortnightly at dairy collection visits. If a change of
w e i g h tb y2k go rm o r ew a sn o t i c e do v e raf o r t n i g h t
participants were asked if they had changed any dietary
habits other than those required for the study. If volun-
teers were having difficulty incorporating the dairy into
their diet, they were offered an appointment with a
registered nutritionist to discuss ways of incorporating
dairy into their diet. For those participants who were
randomised to the HD arm in the first 6 months, a fol-
low-up phone call was made approximately 2 weeks
a f t e rt h e yc r o s s e do v e rt ot h eL Dt r e a t m e n t ,t oc h e c k
compliance with the reduced dairy intake.
Low dairy control
When undertaking the LD treatment participants were
instructed to consume their normal diet but to consume
no more than 1 serve of dairy/day. Dairy products were
not provided during this phase of the study as this level
of intake reflected participants typical habitual intake.
Clinic assessments
Participants had fasting clinic assessments conducted
over two consecutive mornings at baseline, 6, and 12
months. Total testing time took approximately 3.5
hours. Water only was permitted on the morning of
testing and participants were instructed not to under-
take any physical activity prior to testing.
Anthropometric and body composition measures
The primary cardiometabolic outcome measure was
waist circumference. Other anthropometric measures
included body weight, BMI, hip circumference, total
body fat, and abdominal fat.
Waist and hip circumference were measured accord-
ing to the International Standards for Anthropometric
Assessment [38], with the subject in a relaxed standing
position with arms folded across the chest. Waist cir-
cumference was measured at the narrowest point
b e t w e e nt h el o w e rc o s t a lb o r d e r( 1 0
th rib) and the most
superior aspect of the iliac crest. If an obvious waist nar-
rowing was not evident, the measurement was taken at
the midpoint between the inferior costal border and the
iliac crest. Hip circumference was measured around the
buttocks at the level of their greatest posterior protuber-
ance, with feet positioned together. Three measures of
each were taken by the same assessor, and the average
value for each calculated. When possible, the same
assessor measured the same subjects at each visit.
Weight was measured using electronic digital scales
(Tanita Ultimate Scale, Tanita Corporation, Tokyo,
Japan) to the nearest 0.2 kg. Height was measured using
a wall mounted stadiometer (SECA, Hamburg, Ger-
many), and BMI was subsequently calculated as weight
(kg)/height(m
2). Body composition measures (total body
and abdominal fat, lean mass and bone mineral density)
were collected by DEXA (Lunar Prodigy, Lunar Radia-
tion Corp., Wisconsin, USA).
Cardiometabolic measurements
Cardiometabolic outcomes included systolic and diasto-
lic blood pressure, arterial compliance, resting metabolic
rate (RMR), fasting plasma glucose, triglycerides, HDL,
LDL, total cholesterol, and hs-CRP (high sensitivity C-
reactive protein, as a measure of chronic inflammation
associated with adiposity).
Blood pressure and arterial compliance were measured
using the HDI/PulseWave™Cardiovascular Profiler
(model CR-2000, Hypertension Diagnostics Inc™,
Eagen, MN, USA). Three measures were taken and the
average values calculated. RMR was measured by
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ment System, PARV O Medics, Sandy, Utah USA).
At each visit, blood samples were collected by veni-
puncture into 9 mL EDTA tubes for plasma lipids and
hs-CRP, and into 6 ml sodium citrate tubes for plasma
glucose. Within two hours, blood samples were sepa-
rated by centrifugation (Universal 32R, Hettich Zentrifu-
gen, Germany) and stored at -80 degrees so samples
could be processed in batches to reduce the effects of
interassay variability. Plasma lipids (plasma total choles-
terol, HDL cholesterol, triglyceride concentrations), glu-
cose and hs-CRP were measured using an automated
spectrophotometric analyser (Konelab, Model 20xTi;
Thermo Electon, Waltham, MA, USA) with standard
kits. LDL cholesterol was estimated using the Friedewald
formula, a procedure which correlates highly with direct
ultracentrifuge measurement [39]. The triglyceride con-
centration was determined as the average of the values
for the two separate blood samples taken at each assess-
ment time point.
Dietary measurements and physical activity
A 3-day weighed food record (WFR) was completed at
baseline, 6, and 12 months. Individuals were required to
record all food and beverages consumed over a 3 day
period (2 week days and 1 weekend day), including
quantities in grams. Food and beverages were subse-
quently entered into a computer software program
(FoodWorks Professional Edition 2009 using food com-
position data from AUSNUT 2007 and NUTTAB 2006)
for detailed dietary analyses to provide average daily
nutrient intakes. A food frequency questionnaire (FFQ)
was administered at baseline to gain an accurate indica-
tor of dairy consumption over the previous 12 months
prior to entry into the trial. The FFQ requests informa-
tion relating to food choices, frequency, portion size,
quantity and consumption rate of different food and
beverage items [40]. The FFQ is a validated and reliable
measure of dietary intake for use in epidemiological stu-
dies within the Australian population [41-43].
A 3-day physical activity diary (PAD) [44] was com-
pleted over the same 3 days as the WFR. For each 15
minute period subjects estimate the level of physical
activity they were engaging in. Values were based on the
dominant activity for that period, ranging from 1) sleep-
ing, to 9) intense manual work or high intensity sport.
The estimated energy cost in kcal/kg/15 min for each of
the nine activity levels is used to calculate daily energy
expenditure. This tool has been validated for use in
adult populations [44].
Data analysis
One-way ANOVA and Chi square were used to compare
baseline demographic, cardiometabolic and dietary
characteristics between those who completed the 12
month study (completers, n = 36), and those who dropped
out of the study (n = 25). Two-sample t-tests were per-
formed to determine whether there were any significant
differences in any of the cardiometabolic or dietary factors
at baseline between those randomised to HD in the first
phase and those randomised to LD. Carry-over, treatment
and period effects were tested according to Jones and Ken-
ward [36]. To test for any carry-over effects, two-sample
t-tests were performed to compare the sum of the cardio-
metabolic outcome variables (body composition, blood
pressure and arterial compliance, RMR and blood mea-
sures), at the end of each period in the two groups of parti-
cipants (those who started in HD and those who started in
LD). There were no significant differences in the sum of
outcome scores between the two groups. To test for any
period effects, two-sample t-tests were performed to com-
pare differences in cardiometabolic outcomes between the
two diet periods (end of HD - end of LD) in the two
groups. There were no significant differences in the change
score for the two groups, indicating no period effects. We
tested for any seasonal effects, to determine whether
results differed for those who undertook HD in summer or
winter. Using two-sample t-tests, there were no significant
differences in scores for those who undertook HD in sum-
mer versus those who undertook HD in winter. To test for
treatment effects, the difference in outcome scores
between the first and second periods were calculated for
the two groups, and these values were compared using
two-sample t-tests. These results were confirmed with
paired t-tests to compare the within-individual measure-
ments at the end of each dietary phase. Paired t-tests were
also used to compare the mean change of each cardiome-
tabolic factor within each dietary phase. This takes into
account the starting point for each person for each period.
Paired t-tests were used to determine whether there
were any changes in diet (total energy, macronutrient
intakes) between the two diet phases. Linear regression
analyses were performed to determine whether any
changes in dietary variables between the two diet phases
correlated with any changes in cardiometabolic out-
comes. All statistical analyses were conducted using
SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL,
USA). Data are presented as means ± standard error of
the mean (SEM) unless otherwise stated. P <0 . 0 5w a s
considered significant for the primary outcome mea-
sured. Bonferroni adjustment was applied to the level of
significance for secondary outcomes to reduce the risk
of Type I error due to multiple comparisons.
Results
Participants
Of 84 people who were initially screened, 71 were eligi-
ble to participate, gave consent and were enrolled and
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female), completed a baseline assessment. A further 25
participants withdrew during the course of the study.
Due to the disproportionate number of drop-outs from
each diet (17 initially randomised to LD and 8 rando-
mised to HD) the numbers remaining on each diet at
the end of the study were unequal. In total, 36 partici-
pants (23 initially allocated to HD and 13 allocated to
LD), aged 18 to 71 years, completed the 12-month
study. A summary of randomisation and participant
flow is shown in Figure 1. The overall rate of attrition
was 49.3%. At baseline, there were no significant differ-
ences (data not shown) in sex distribution, age, total
energy or macronutrient intakes, physical activity levels,
or cardiometabolic characteristics between those who
withdrew during the study period (n = 25) and those
who completed the study (n = 36).
The most frequent reasons cited for leaving the study
were due to changes that the participant intended to
make that would interfere with study outcomes, such as
starting a new medication or changing diet or exercise
habits. Other explanations for drop-out given were for
personal reasons or because they were moving away
from the study location, time commitment, or an inabil-
ity to consume 4 serves of dairy/day while in the HD
phase. Four participants in the LD group withdrew prior
to, or at the time of crossover as they were unwilling to
increase their dairy consumption.
There were no statistically significant differences in
any of the cardiometabolic or dietary factors at baseline
between those randomised to HD in the first phase and
those randomised to LD. There was no evidence of any
period, order or seasonal effects. The change between
the two dietary phases in the primary outcome measure,
waist circumference, in addition to secondary outcomes
including body composition, blood pressure, blood lipids
and glucose, arterial stiffness and RMR, did not differ
significantly between those who consumed HD in the
f i r s tp h a s ea n dt h o s ew h oc o n s u m e dH Di nt h es e c o n d
phase. Total energy intake and physical activity at the
end of the two diet phases did not differ according to
order of intervention.
Figure 1 Participant flow and attrition. Participant flow through the study, showing study design with participant progression and attrition
following initial randomisation to the HD and LD diets. HD, high dairy; LD, low dairy.
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At baseline, the mean intake of dairy (sum of milk,
cheese, yogurt, ice-cream, and butter/margarine) was 1.9
± 0.9 serves/day. During the HD phase, the intake of
dairy foods was 28.1 ± 2.6 serves/week, equating to 4
serves/day (comprising 25.2 ± 3.1 serves of supplied
dairy and 2.9 ± 2.4 serves of own dairy/week). The
mean daily intakes of dairy products in the HD phase
were 535 mL of plain milk, 428 mL of flavoured milk,
257 g of yogurt, and 81 g of custard.
Energy intake differed between diets (intakes taken
from 3-day WFR’s shown in Table 1). Mean energy
intake was significantly higher (1120 ± 360 kJ/day; p =
0.004) during the HD phase, than during the LD control
phase. The increased dairy intake during the HD phase
was associated with a significantly higher intake of pro-
tein (p < 0.001) and carbohydrate (p = 0.03). The
intakes of macronutrients as a proportion of total energy
in the diet also different significantly between the two
phases, with a higher proportion of total energy from
protein (p = 0.011), and a lower proportion from fat (p
= 0.006) during HD. Total sugar intake was significantly
higher during HD compared with LD (p <0 . 0 0 1 ) .C a l -
cium intake was significantly higher (p < 0.001) during
HD (1452 mg/day) compared with LD (723 mg/day).
Anthropometric and body composition measures
There was no significant difference in the primary cardi-
ometabolic outcome, waist circumference, between the
HD and LD phases of the study (Table 2). Nor were
there any significant differences in body weight, hip
circumference, BMI, total body fat or abdominal fat
between the two diet conditions. However, the mean
changes in body weight, BMI, and hip circumference
within the HD phase (change over 6 month period)
were greater than within the LD phase (Table 3).
Cardiometabolic outcomes
There were no significant changes in RMR or total
energy expenditure, systolic and diastolic blood pressure,
fasting blood glucose, total, HDL or LDL cholesterol,
triglycerides or hs-CRP. There was a slight decrease (1.0
± 0.5 ml/mmHg × 100; p = 0.032) in small arterial elas-
ticity index (SAEI) at the end of HD (Table 2), but this
was not statistically significant after Bonferroni adjust-
ment. Similarly, there were no differences in the amount
of change within each period for any of these variables.
Discussion
This relatively long-term crossover intervention study
examined effects of increasing the intake of reduced fat
dairy food in habitually low dairy consumers, without
restricting overall energy intake. Participants increased
their energy intake whilst consuming more dairy food,
yet a comparison of absolute values at the end of each
period showed no significant difference in body weight,
body fat, or abdominal adiposity. The difference in
energy intake of approximately 1120 kJ/day between LD
and HD over 6 months equates to a difference of > 30
000 kJ/month, which would be expected to contribute
to a weight gain of ~1 kg/month or a 6 kg difference in
body weight over the 6 month HD diet period compared
Table 1 Average daily dietary intakes at end of LD and at end of HD, from 3-day weighed food records
Daily dietary intakes Baseline End HD End LD Change HD-LD P-value*
n3 0 3 2 3 2 3 2
Total energy (MJ) 8.71 ± 0.61 8.84 ± 0.41 7.73 ± 0.37 1.12 ± 0.36 < 0.01
Protein (g) 97 ± 6 110 ± 5 84 ± 3 26 ± 5 < 0.001
Carbohydrate (g) 226 ± 17 232 ± 12 209 ± 13 24 ± 10 0.03
Fat (g) 78 ± 7 69 ± 5 65 ± 4 4 ± 5 0.42
SFA (g) 31 ± 4 27 ± 2 23 ± 2 3 ± 2 0.11
PUFA (g) 11 ± 1.0 9 ± 0.9 10 ± 0.9 -1.0 ± 1.0 0.32
MUFA (g) 28 ± 3 23 ± 2 22 ± 1 1.1 ± 1.9 0.56
Alcohol (g) 7 ± 2 10 ± 2 8 ± 2 2.4 ± 1.7 0.16
Sugars (g) 110 ± 10 127 ± 8 92 ± 7 36 ± 5 < 0.001
Fibre (g) 24 ± 2 21 ± 2 22 ± 2 -0.8 ± 1.2 0.50
Calcium (mg) 1112 ± 146 1452 ± 68 723 ± 35 730 ± 74 < 0.001
Protein (% of total energy) 19 ± 0.8 22 ± 0.9 19 ± 0.7 2.6 ± 1.0 0.01
Carbohydrate (% of total energy) 40 ± 1.4 40 ± 1.2 39 ± 1.2 0.9 ± 1.4 0.52
Fat (% of total energy) 33 ± 1.1 28 ± 1.0 31 ± 0.9 -3.0 ± 1.0 < 0.01
Sugars (% of total energy) 23 ± 1.3 25 ± 1.1 20 ± 0.9 4.9 ± 0.8 < 0.001
Values are means ± SEM. HD, high dairy; LD, low dairy; MUFA, monounsaturated fatty aid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid. *Probability
of differences between the end of the 2 diet periods (paired sample t-tests)
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weight increase within the HD phase (mean increase of
1.8 ± 0.4 kg) than what may have been expected consid-
ering the large increase in energy intake. There was no
evidence of an increase in either RMR or physical activ-
ity during the HD phase which might have balanced the
increased energy intake. However faecal excretion of fat
was not assessed and the increased calcium intake dur-
ing HD might have promoted the formation of calcium-
soaps in the intestine resulting in increased fat excretion
and reduced fat absorption, thus accounting for only the
small weight increase observed despite a higher energy
intake during HD.
The finding of minimal weight gain despite a higher
energy intake with HD is similar to that of Zemel et al.
[45] who compared a high vs. low intake of dairy intake
on weight maintenance following a period of weight
loss. Participants were randomised to either recom-
mended dairy (> 3 servings/day) or low dairy (< 1 ser-
ving/day) for a 6 month maintenance phase. The
recommended dairy group had a significantly higher
energy intake compared to the low dairy group, but
exhibited no gain in body weight, waist circumference,
total body fat, or abdominal fat.
Two other studies have shown beneficial effects from
high dairy and calcium intakes on anthropometric mea-
sures without energy restriction. Zemel et al. [19]
demonstrated that increasing the dairy intake in obese
African Americans to 3 servings/day in the absence of
energy restriction for 24 weeks had beneficial effects on
body composition, reducing total body and abdominal
fat and increasing lean mass, while maintaining a stable
body weight. In a 2-year exercise intervention study, Lin
et al. [46] showed that high intakes of dairy calcium
(but not non-dairy calcium), adjusted for energy intake,
were associated with weight loss and body fat loss, inde-
pendent of exercise. They also noted an interesting
interaction between calcium and energy intake, whereby
in those with lower energy intakes, total or dairy cal-
cium, but not energy intake, negatively predicted weight
and fat mass. In those with energy intakes greater than
the mean (~7850 kJ), energy intake, but not calcium
intake positively impacted on body weight and body fat.
There was no difference in calcium intake between the
low and high energy intake groups.
Furthermore, two studies [9,10] have reported similar
weight and fat loss in high-dairy calcium groups in com-
bination with energy restriction (500 kcal/day deficit),
Table 2 Cardiometabolic variables at baseline, at end of LD and at end of HD
Variable Baseline End HD End LD Change HD-LD P-value*
n 3 63 63 6 3 6
RMR (MJ/d) 6.7 ± 0.3 6.9 ± 0.3 6.9 ± 0.3 0.06 ± 0.3 0.86
Energy expenditure (MJ/d) 16.1 ± 0.7 16.1 ± 0.7 15.9 ± 0.7 0.3 ± 0.4 0.51
Body weight (kg) 88.6 ± 2.9 90.8 ± 3.0 90.3 ± 3.0 0.5 ± 0.5 0.29
BMI (kg/m
2) 31.5 ± 0.9 32.2 ± 1.0 32.0 ± 0.9 0.2 ± 0.2 0.20
Waist circumference (cm) 98.2 ± 2.4 98.9 ± 2.4 98.3 ± 2.5 0.6 ± 0.6 0.33
Hip circumference (cm) 114.3 ± 2.0 115.8 ± 2.1 115.4 ± 2.1 0.5 ± 0.3 0.18
Body fat (%) 43.0 ± 1.5 43.6 ± 1.5 43.5 ± 1.5 0.1 ± 0.3 0.67
Fat mass (kg) 36.6 ± 1.9 38.0 ± 2.0 37.7 ± 2.0 0.3 ± 0.4 0.46
Lean mass (kg) 48.0 ± 1.9 48.5 ± 1.9 48.3 ± 1.9 0.1 ± 0.3 0.60
Abdominal fat (kg) 2.6 ± 0.2 2.7 ± 0.2 2.7 ± 0.2 -0.01 ± 0.03 0.71
Bone mineral density (g/cm
2) 1.3 ± 0.02 1.3 ± 0.02 1.2 ± 0.02 0.002 ± 0.004 0.65
SBP (mm Hg) 125.9 ± 2.2 131.8 ± 2.6 130.9 ± 2.3 0.9 ± 1.4 0.51
DBP (mm Hg) 69.2 ± 1.4 70.3 ± 1.5 71.3 ± 1.3 -1.0 ± 1.1 0.34
LAEI (ml/mm Hg × 100) 16.0 ± 4.7 14.9 ± 4.4 15.4 ± 5.4 -1.0 ± 0.8 0.25
SAEI (ml/mm Hg × 100) 7.0 ± 0.7 6.3 ± 0.6 7.3 ± 0.8 -1.0 ± 0.5 0.03
Plasma glucose (mmol/L) 5.8 ± 0.1 5.9 ± 0.1 5.8 ± 0.1 0.04 ± 0.5 0.64
Triglycerides (mmol/L) 1.1 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 0.1 ± 0.3 0.21
Total cholesterol (mmol/L) 5.1 ± 0.2 5.4 ± 0.2 5.4 ± 0.2 -0.01 ± 0.5 0.86
HDL cholesterol (mmol/L) 1.4 ± 0.1 1.4 ± 0.1 1.4 ± 0.1 -0.02 ± 0.1 0.51
LDL cholesterol (mmol/L) 3.7 ± 0.1 3.9 ± 0.1 3.9 ± 0.1 0.002 ± 0.4 0.98
hs-CRP (mg/L) 6.4 ± 1.7 4.4 ± 0.8 4.9 ± 1.4 -0.5 ± 5.1 0.57
Values are means ± SEM. BMI, body mass index; DBP, diastolic blood pressure; HD, high dairy; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive
protein; LAEI, large arterial elasticity index; LD, low dairy; LDL, low-density lipoprotein; RMR, resting metabolic rate; SAEI, small arterial elasticity index; SBP, systolic
blood pressure. *Probability of differences between the end of the 2 diet periods (paired sample t-tests)
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for 12 months, despite a higher energy intake (~150
kcal/day) in the high dairy groups. Together, these data
suggest that high dairy consumers appear to be able to
consume more food without adversely affecting body
composition.
It is currently thought that dairy foods may alter over-
all energy balance by increasing fat oxidation and by
decreasing the absorption of fatty acids. A number of
studies have shown that increased dietary calcium
intake, including calcium from dairy [47-50], increases
fat oxidation. The effects of calcium on fat mass are
proposed to occur via the regulation of the calcitrophic
hormones, parathyroid hormone (PTH) and 1,25-dihy-
droxyvitamine D (1,25(OH)2D). These hormones are
produced in response to low-calcium diets, stimulating
the influx of intracellular calcium in adipocytes, promot-
ing lipogenesis and increased adiposity [51,52]. Increas-
ing dietary calcium can suppresses circulating PTH and
1,25(OH)2D, with a corresponding increase in lipolysis
and fat oxidation [47,51,52]. Findings to date suggest
the impact of calcium on adiposity may be dependent
upon energy intake, and likely enhanced in a state of
negative energy balance. Further exploring this possibi-
lity, Melanson et al. [48] found that a high dairy and
calcium diet for 1 week increased fat oxidation under
conditions of acute energy deficit, but not when energy
was maintained. In contrast, in the absence of energy
deficit Gunther et al. [47] observed a significant increase
in whole-body fat oxidation after 1 year of increased
dairy product consumption, compared with a low dairy
group control, yet no weight change was observed,
despite a slightly higher energy intake in the dairy inter-
vention group compared with control [47], as was the
case in the present study.
The small increase in body weight despite the higher
energy intake during HD in the present study does not
appear to be due to an increase in fat oxidation. Energy
expenditure estimated from 3-day physical activity dia-
ries was slightly higher at the end of the HD phase than
at the end of LD, but this was not statistically signifi-
cant. There was no difference in RMR between the two
diet phases, although it is possible that the assessment
of RMR using indirect calorimetry may not have been
sensitive enough to detect a small change in metabolic
rate. Those studies that have reported increased fat oxi-
dation in response to increased dairy or calcium intakes
have typically used whole-room indirect calorimetry
[48,49], enabling measurement of energy expenditure
and substrate oxidation over 24 hours during different
levels of activity (i.e. during sleep and active periods), or
have used the doubly labeled water technique [50].
Thus, while our study did not demonstrate an increase
in fat oxidation with HD, it is possible that our method
of assessing this outcome was not sensitive enough to
detect any small change.
It is more feasible that the increase in dairy calcium
during the HD phase reduced fat absorption, thereby
preventing more substantial gains in body weight or fat
mass. Calcium intake during the HD phase, 1452 mg/
day, is very similar to the calcium intake of 1325 mg/
day for the dairy group (approximately 3 serves of dairy/
day) during weight maintenance in the Zemel et al. [45]
study where similarly, despite a higher energy intake
compared to the low dairy group, the dairy group exhib-
ited no gain in body weight, waist circumference, total
body fat, or abdominal fat. The calcium intake during
HD is also comparable to a study conducted over a
similar time frame (24 weeks) and without energy
restriction, which showed a decrease in total body fat
and trunk fat, and increase in lean mass following a HD
diet (3 serves of dairy, 1200 mg/day of calcium) [19].
Several human studies have demonstrated that dietary
calcium increases faecal fat excretion by forming
Table 3 Mean change in cardiometabolic variables during
HD and LD
Variable Mean
change
during HD
Mean
change
during LD
P-value*
n3 6 3 6
Body weight (kg) 1.8 ± 0.4 0.2 ± 0.5 0.01
BMI (kg/m
2) 0.6 ± 0.1 0.0003 ± 0.2 0.01
Waist circumference (cm) 0.8 ± 0.6 -0.8 ± 0.6 0.14
Hip circumference (cm) 1.5 ± 0.4 0.005 ± 0.4 0.03
Body fat (%) 0.7 ± 0.3 0.1 ± 0.3 0.28
Fat mass (kg) 1.3 ± 0.4 0.2 ± 0.3 0.05
Lean mass (kg) 0.3 ± 0.3 0.01 ± 0.3 0.60
Abdominal fat (kg) 0.09 ± 0.03 0.07 ± 0.03 0.81
Bone mineral density (g/cm
2) -0.004 ±
0.003
-0.004 ±
0.004
0.96
SBP (mm Hg) 4.3 ± 1.6 0.8 ± 1.5 0.19
DBP (mm Hg) 0.6 ± 0.8 2.0 ± 1.0 0.40
LAEI (ml/mm Hg × 100) -0.6 ± 0.4 0.5 ± 0.9 0.33
SAEI (ml/mm Hg × 100) -0.9 ± 0.4 0.6 ± 0.6 0.07
Plasma glucose (mmol/L) -0.008 ±
0.09
-0.03 ± 0.09 0.87
Triglycerides (mmol/L) 0.2 ± 0.07 -0.03 ± 0.06 0.09
Total cholesterol (mmol/L) 0.08 ± 0.07 0.2 ± 0.1 0.39
HDL cholesterol (mmol/L) -0.01 ± 0.03 0.03 ± 0.03 0.31
LDL cholesterol (mmol/L) 0.09 ± 0.05 0.2 ± 0.1 0.53
hs-CRP (mg/L) -1.2 ± 1.4 -0.09 ± 0.9 0.54
Values are means ± SEM. BMI, body mass index; DBP, diastolic blood pressure;
HD, high dairy; HDL, high-density lipoprotein; hs-CRP, high sensitivity
C-reactive protein; LAEI, large arterial elasticity index; LD, low dairy; LDL,
low-density lipoprotein; SAEI, small arterial elasticity index; SBP, systolic blood
pressure. *Probability of differences between the 2 means (paired sample
t-tests)
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ing fatty acid absorption, resulting in energy and weight
loss [53-55]. Jacobsen et al. [53] showed that a short-
term increase in calcium intake (1800 mg/day) from
reduced-fat dairy products, in conjunction with normal
protein intake (15% of total energy), increased faecal fat
and energy loss by approximately 312 kJ/day, which cor-
responds to a weight loss of 3.5 kg/year. Interestingly,
there was no effect on energy loss when protein intake
(23% of total energy) was high. Jacobsen et al. [53] sug-
gest that in the presence of high dietary protein, more
calcium may be absorbed, and secondly may bind to
protein, making less available to bind with fatty acids. In
our study, calcium intakes were a little lower, but 22%
of energy was derived from protein at the end of the
HD phase, which may have confounded the ability of
calcium to exert even greater effects.
We cannot be absolutely certain that energy intake
was greater whilst participants were assigned to HD,
even though our results indicate this was the case. The
lack of contact with investigators while in the LD phase
may have led participants to under-report intakes during
this phase. As they were not visiting the centre fort-
nightly and receiving the same attention as the HD
group, they may have been less likely to pay close atten-
tion to what they were eating, thus introducing selective
bias.
The increased consumption of dairy foods did not
affect other cardiometabolic parameters including blood
pressure, which is postulated to benefit from dairy con-
sumption [24,56-58]. However, blood pressure reduc-
tions are usually demonstrable only in hypertensives and
our population was clearly normotensive. A 2.9 mmHg
r e d u c t i o ni ns y s t o l i cb l o o dp r e s s u r ew a so b s e r v e di na
recent study of similar design, whereby overweight parti-
cipants consumed 3 serves of low-fat dairy/day for 8
weeks and then crossed-over to a carbohydrate-rich
control period for 8 weeks [58]. However, the baseline
blood pressure was considerably higher for these partici-
pants (mean systolic blood pressure 135 mmHg, diasto-
lic blood pressure 88 mmHg than in the present study
(systolic blood pressure 126 mmHg, diastolic blood
pressure 69 mmHg).
There was a slight reduction in SAEI in this study at
the end of HD compared with the LD control period.
However, this cannot be regarded as significant due to
the possibility of a type I error resulting from multiple
comparisons. It was encouraging to observe that a high
consumption of reduced fat dairy foods did not have an
adverse effect on blood lipids, blood glucose or hs-CRP.
There was no significant change in bone mineral den-
sity; however, a longer time frame may be required to
detect this. The shorter-duration study by van Meijl and
Mensink [58] similarly did not find any change in other
cardiometabolic risk parameters, including serum lipids,
plasma glucose, insulin, CRP, or body weight between
the two diet conditions, although they found that low-
fat dairy consumption had a beneficial effect on the
action of the inflammatory marker TNF-a [59]. The
lack of any beneficial effect of HD vs. LD is also consis-
tent with Wennersberg et al. [60], who examined dairy
intake in relation to components of the metabolic syn-
drome in overweight adults. In this parallel-group inter-
vention trial, overweight adults were similarly assigned
to either a milk diet (3-5 portions/day) or control (habi-
tual) diet for 6 months and no significant differences
were found in body weight, body composition or other
components of the metabolic syndrome. Perhaps the
time frame in the present study and that of Wenners-
berg et al. [60] may have been too short to observe any
improvement in cardiometabolic parameters.
Some limitations to the present study must be
acknowledged. The type of dairy foods provided to par-
ticipants may have influenced their ability to incorporate
the dairy into their diet and subsequent energy balance.
T h ei n c r e a s ei ne n e r g yi n t a k ed u r i n gt h eH Dp h a s ea n d
subsequent small gain in body weight reflects an inabil-
ity to incorporate the dairy food into the diet. Partici-
pants were predominantly provided with milk, yogurt
and custard, all rich in whey protein. It may have been
easier for participants to incorporate cheese products (e.
g., cream cheese, cheddar cheese, ricotta) into their diet
without an overall increase in energy intake.
Additionally, a larger sample size would have been
more desirable. Sustaining the involvement of indivi-
duals and compliance with the dietary requirements
throughout the lengthy intervention period and data col-
lection process presented a major challenge. The diffi-
culties in running long term dietary intervention trials
based on our experiences in the present study and the
biases incurred as a result of high drop-out, including
the general applicability of results and effect on power,
are summarised in a separate manuscript. A larger sam-
ple in the current study would have permitted us to
detect smaller changes in cardiometabolic measures that
may be more likely in dietary intervention studies with-
out energy restriction. Another acknowledged limitation
is the lack of a wash-out period. Our simple design
(without a wash-out and re-assessment of baseline) is
unable to accurately determine whether there were any
carry-over effects. However, the exceptionally long inter-
vention period (6 months) was expected to enable com-
plete habituation to the alternate diet.
Despite these challenges, there are a number of
strengths to the present study. This is one of the first
intervention trials examining dairy intake without energy
restriction, in relation to cardiometabolic health. Adher-
ence to consuming 4 serves of dairy food/day during the
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increase the dairy consumption of low consumers to
meet the current Australian Dietary Guidelines recom-
mendation for 2 to 3 serves of milk, yogurt or cheese
each day for women and 2 to 4 serves for men [34,61].
Consequently recommended intakes of calcium, 31%
higher at the end of HD compared with baseline, were
also met. Of the 37 participants who completed the HD
intervention and interview, 27 reported that at the end
o ft h es t u d yt h e yw o u l db em o r el i k e l yt oc o n s u m e
more dairy than they did prior to the study. Although
the accuracy of actual dietary intake from self-reported
food records may be poor [62], a strength of the study
is that participants served as their own control, so that
they presumably would have over- or under-reported
intakes to a similar extent at each time point.
Conclusions
Few studies have assessed the effects of dairy foods on
measures of body weight and other cardiometabolic
parameters without restricting energy intake. The results
from our clinical trial are consistent with an anti-obesity
effect of dairy foods, suggesting that recommended
intakes of reduced fat dairy products may be incorpo-
rated into the diet without weight or fat gain. If overall
energy intake can be carefully controlled, reduced fat
dairy products may be utilised for preventing and mana-
ging overweight and obesity.
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